Plus Therapeutics Announces Private Placement Financing of up to 18 Million
PSTV Stock | USD 0.68 0.05 6.84% |
Slightly above 64% of Plus Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Plus Therapeutics suggests that many traders are alarmed. Plus Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Plus Therapeutics' earnings reports, geopolitical events, and overall market trends.
Plus |
6.5 million in upfront gross proceeds with the potential to receive up to an additional 11.5 million in potential warrant exercise proceeds for an aggregate of up to approximately 18 million in total gross proceedsAUSTIN, Texas, May 06, 2024 -- Plus Therapeutics, Inc. , a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that it
Read at finance.yahoo.com
![]() |
Plus Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Plus Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Plus Therapeutics Fundamental Analysis
We analyze Plus Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Plus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Plus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Plus Therapeutics is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Plus Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Plus Therapeutics stock to make a market-neutral strategy. Peer analysis of Plus Therapeutics could also be used in its relative valuation, which is a method of valuing Plus Therapeutics by comparing valuation metrics with similar companies.
Peers
Plus Therapeutics Related Equities
ENVB | Enveric Biosciences | 32.08 | ||||
ZURA | Zura Bio | 13.33 | ||||
IMMX | Immix Biopharma | 12.66 | ||||
TARA | Protara Therapeutics | 10.32 | ||||
MNPR | Monopar Therapeutics | 7.66 | ||||
QNRX | Quoin Pharmaceuticals | 0.32 | ||||
SRZN | Surrozen | 0.00 | ||||
PALI | Palisade Bio | 0.12 | ||||
HOTH | Hoth Therapeutics | 0.43 | ||||
REVB | Revelation Biosciences | 1.41 | ||||
DRMA | Dermata Therapeutics | 1.72 | ||||
VRAX | Virax Biolabs | 2.34 | ||||
ATXI | Avenue Therapeutics | 4.55 |
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.